MetaCap

Generate Biomedicines (GENB) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Generate Biomedicines is the larger company by market cap ($1.23 billion vs $1.21 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GENB-24.58%MLYS-53.32%
+67%+4%-59%
Feb 27, 20261 yearNov 20, 2026
GENB-24.58%MLYS-53.32%
+42%-8%-58%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GENB versus MLYS key metrics
MetricGENBMLYS
Share price$9.54$13.66
Market cap$1.23B$1.21B
1-day change-8.00%-3.53%
YTD return—-62.36%
1-year return—-67.38%
EPS (TTM)$-2.49$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-154.65M
52-week high$22.67$44.13
52-week low$9.40$13.57
Distance from 52-week high-57.92%-69.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+183.02%+218.89%
Average volume1.24M1.55M
Shares outstanding129.10M88.56M
Employees31276
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Generate Biomedicines

GENB stock →

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

GENB vs MLYS FAQ

Which is bigger, Generate Biomedicines or Mineralys Therapeutics?

Generate Biomedicines (GENB) is larger, with a market capitalization of $1.23B compared with $1.21B for Mineralys Therapeutics (MLYS).

Are Generate Biomedicines and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons